Subscribe
360b-shutterstock-com-2-
360b / Shutterstock.com
6 August 2015Americas

European Commission approves Pfizer’s buyout of Hospira

The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

More on this story

Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB